SABCS18 5 Key Highlights
Last month BCRF attended the 41st Annual San Antonio Breast Cancer Symposium (SABCS), the largest annual breast cancer meeting in the world. This year’s meeting hosted more than 7,500 attendees from 90 countries.
How patients have transformed a medical meeting about breast cancer
Advocates have become an essential part of the annual San Antonio Breast Cancer Symposium, an influential medical meeting. Former oncologist Elaine Schattner explains the change and its importance.
Ann Loeser’s SABCS18 Summary
Pacific Northwest Metastatic Conference
Elaine Schattner on TailorX
These results have the potential to reduce overtreatment of breast cancer—stopping patients’ unnecessary exposure to chemotherapy—in a large fraction of cases. The public health implications are huge.
Dr. Attai ASCO2018 TailorX Study Results
4 June 2018 The American Society of Clinical Oncology (ASCO) annual meeting, a gathering of over 40,000 oncology specialists, was held this past weekend in Chicago. One of the studies that received a significant amount of press attention was the TAILORx study. There are several genomic tests which evaluate a tumor’s DNA to better determine…
Dr. Attai Highlights from the 2018 American Society of Breast Surgeons Annual Meeting
10 May 2018 The American Society of Breast Surgeons held their Annual Meeting in Orlando, FL from May 2nd – 6th. As usual, it was well attended – the meeting is known for being very practical and full of information that breast surgeons can bring back to their practices to help improve patient care. I’ve…
TailorX Article in Vogue
An influential new study finds many women with early-stage breast cancer can now avoid chemotherapy—safely and effectively.
ASCO2018 Sacituzumab Data for Heavily Pretreated MBC
ASCO2018 Taselisib with Faslodex for MBC
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.
2018/05/30 HER2+ Combo of pertuzumab-trastuzumab-capecitabine prolongs survival
Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.